Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically (histologically or cytologically) proven (from primary lesion and/or lymph nodes) diagnosis of HPV-positive squamous cell carcinoma of the oropharynx, hypopharynx, or larynx; HPV-positivity will be defined as tumors that are p16-positive by immunohistochemistry~* Clinical stage III or IV disease; note: patients with M1 tumors are not eligible~* Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:~  * History/physical examination within 4 weeks prior to registration, including assessment of weight loss in past 6 months~ * Chest x-ray (or chest computed tomography \[CT\] scan or positron emission tomography \[PET\]/CT scan) within 6 weeks prior to registration~* CT scan or magnetic resonance imaging (MRI) of the head and neck (of the primary tumor and neck nodes) and PET/CT scan~* Zubrod performance status 0-1~* Absolute neutrophil count (ANC) \> 1,800 cells/mm\^3~* Platelets \> 100,000 cells/mm\^3~* Hemoglobin (Hgb) \> 8.0 g/dl (note: the use of transfusion or other intervention to achieve Hgb \> 8.0 g/dl is acceptable)~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \< 2x the upper limit of normal~* Serum creatinine =\< 1.5 mg/dl or institutional upper limit of normal~* Creatinine clearance (CC) \>= 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula~* Negative serum pregnancy test within 7 days prior to start of induction chemotherapy (ICT) for women of childbearing potential~* Women of childbearing potential and male participants are counseled on birth control and must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study (until at least 60 days following the last study treatment)~* Patient must sign study specific informed consent prior to study entry~Exclusion Criteria:~* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years~* Patients with simultaneous primaries or bilateral tumors are excluded~* Patients who have had initial surgical treatment other than the diagnostic biopsy of the primary site or nodal sampling of the neck disease are excluded~* Patients with unknown primary tumor sites are excluded~* Patients who present with a cervical lymph node metastasis of unknown primary origin~* Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable~* Prior radiotherapy that would result in overlap of radiation therapy fields~* Primary site of tumor of oral cavity, nasopharynx, nasal cavity, paranasal sinuses, or salivary glands~* Recurrent head and neck cancer~* Current uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction~* Congestive heart failure with left ventricular ejection fraction \< 20%~* Transmural myocardial infarction within the last 6 months~* Acute bacterial or fungal infection requiring intravenous antibiotics at registration~* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration~* Active lupus erythematosus or scleroderma with ongoing physical manifestations~* Any uncontrolled condition, which in the opinion of the investigator, would interfere in the safe and timely completion of study procedures~* Pregnant or lactating women or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception~* Prior allergic reaction to the study drug(s) involved in this protocol~* Patient is enrolled in another investigational trial

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (paclitaxel, carboplatin, IMRT) (Type: EXPERIMENTAL): INDUCTION: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes. Treatment repeats every 21 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.~CHEMORADIOTHERAPY: At least 2 weeks after completion of induction chemotherapy, patients receive paclitaxel IV over 1 hour weekly and undergo IMRT daily 5 days a week for 5.5 weeks in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).